Brought to you by 
Glaxo Wellcome and PowderJect ink potential $324mm deal
13 Jul 1999
Executive Summary
PowderJect exclusively licensed Glaxo a hepatitis B DNA vaccine and options on 10 other DNA products. Glaxo will pay (uf)$24mm up front ($4mm in license and option fees and $20mm for a 7.7% stake in PowderJect's equity).
Deal Industry
- Biotechnology
- Medical Devices
-
Pharmaceuticals
- Vaccines
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Glaxo Wellcome and PowderJect ink potential $324mm deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice